Prosecution Insights
Last updated: April 19, 2026
Application No. 18/493,142

HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING

Non-Final OA §DP
Filed
Oct 24, 2023
Examiner
GAUGER, PAUL RANDALL
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
3y 1m
To Grant
48%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allow Rate
9 granted / 14 resolved
+4.3% vs TC avg
Minimal -17% lift
Without
With
+-16.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
18 currently pending
Career history
32
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
28.8%
-11.2% vs TC avg
§102
18.9%
-21.1% vs TC avg
§112
19.8%
-20.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 14 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application claims foreign priority to EP22203741.8, filed on 10/26/2022. Status of the Claims Currently, claims 1-18 are pending in the instant application and are examined on their merits. Information Disclosure Statement The Information Disclosure Statements filed on October 24th 2023 (31 references) are in compliance with the provisions of 37 CFR 1.97 and have been considered in full. A signed copy of list of references cited from the IDS is included with this Office Action. Nonstatutory Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-18 provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of copending Application No. 18/596,986 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the instant application are exceedingly overlapping in scope with the claims of the reference application. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim 1 of the instant application recites a compound of formula (I): PNG media_image1.png 254 225 media_image1.png Greyscale Claim 1 of the reference application recites a compound of formula (I): PNG media_image2.png 258 202 media_image2.png Greyscale While the claims at hand are not identical, the scope of the claims is significantly overlapping, and the recited compound of the reference application appears to be embraced by the compound of the instant application. For example, the compounds are overlapping in the following conditions: Formula (I) of the instant application Formula (I) of the reference application - Ring D is a 9-membered bicyclic heteroaryl containing 2 N atoms R1 is C1-6 alkyl R4 is C1-3 alkyl R3 is PNG media_image3.png 108 121 media_image3.png Greyscale A is N, Ring B is a 5-7-membered monocyclic heterocyclyl containing 1 or 2 N atoms, and R5 is C1-6 alkylene-COOH The above conditions are not an exhaustive set; however, they exemplify the overlapping subject matter between the claims of the applications. Furthermore, claims 9 and 10 of the instant application appear to contain compounds which fall squarely within the limitations of claim 1 of the reference application; the compounds including at least the following: PNG media_image4.png 214 308 media_image4.png Greyscale PNG media_image5.png 206 470 media_image5.png Greyscale PNG media_image6.png 187 165 media_image6.png Greyscale As both the instant application and the reference application are drawn to essentially the same subject matter, the claims cannot be considered as patentably distinct from one another. Conclusion Claims 1-18 are rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL RANDALL GAUGER whose telephone number is (571)272-1325. The examiner can normally be reached M-F 7:30-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffery Lundgren can be reached at (571)272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /P.R.G./ Examiner, Art Unit 1629 /JEFFREY S LUNDGREN/ Supervisory Patent Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Oct 24, 2023
Application Filed
Jan 29, 2026
Non-Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599592
THERAPEUTIC SMALL MOLECULES FOR TREATMENT OF PULMONARY HYPERTENSION
2y 5m to grant Granted Apr 14, 2026
Patent 12590089
PROCESSES FOR PREPARING TOLL-LIKE RECEPTOR MODULATOR COMPOUNDS
2y 5m to grant Granted Mar 31, 2026
Patent 12590105
KRAS G12C INHIBITORS
2y 5m to grant Granted Mar 31, 2026
Patent 12570649
ISAVUCONAZONIUM SALTS AND PROCESS FOR PREPARING THEREOF
2y 5m to grant Granted Mar 10, 2026
Patent 12569473
METHODS TO TREAT RESPIRATORY INFECTION UTILIZING CASTANOSPERMINE ANALOGS
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
48%
With Interview (-16.7%)
3y 1m
Median Time to Grant
Low
PTA Risk
Based on 14 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month